The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
about
Palbociclib - from Bench to Bedside and BeyondPalbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast CancerClinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast CancerCDK4/6 inhibition in luminal breast cancerThe Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of JanusTreatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancerPharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancerProfile of palbociclib in the treatment of metastatic breast cancerHormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment ConsiderationsThe emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancerClinical utility of letrozole in the treatment of breast cancer: a Chinese perspectiveNovel Molecular Markers for Breast CancerCurrent Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast CancerDelaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerRegulation of steroid hormone receptors and coregulators during the cell cycle highlights potential novel function in addition to roles as transcription factorsNeoadjuvant endocrine therapy in breast cancer: current role and future perspectivesPotential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancerOptimal management of hormone receptor positive metastatic breast cancer in 2016Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast CancerDevelopment of cell-cycle checkpoint therapy for solid tumorsBreast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and TechnologiesTreating Elderly Patients With Hormone Receptor-Positive Advanced Breast CancerCurrent medical treatment of estrogen receptor-positive breast cancerRB1: a prototype tumor suppressor and an enigmaAGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015.CIViC databaseIntegrative clinical genomics of advanced prostate cancer.Targeting the RB-E2F pathway in breast cancerAccurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkersTargeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancersApproaches to modernize the combination drug development paradigmRecent developments and translational aspects in targeted therapy for metastatic breast cancerImpact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancerPalbociclib: A New Option for Front-Line Treatment of Metastatic, Hormone Receptor-Positive, HER2-Negative Breast CancerFOXM1 in sarcoma: role in cell cycle, pluripotency genes and stem cell pathwaysReview of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrantMajor clinical research advances in gynecologic cancer in 2015Recent advances in the medical treatment of breast cancerSystemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelinesEndocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers
P2860
Q26738979-DF1CB34F-4624-4FF1-B082-8F804B3F92E7Q26738982-21C0AB9B-0DDF-4AA3-AF1F-DC74B3F5E7B6Q26738985-25B0FA0D-BA5E-4DF4-979C-A42E6042D071Q26739836-B42A38F0-4086-4006-A728-691169E8F428Q26740184-695C15EE-0B57-4BD8-9176-B46463A498B1Q26741153-6EAB9708-66E8-4360-B9D2-0EF03D63B4D2Q26746212-F843889E-27CD-4CCD-8C64-41C3DD1B1CD4Q26747737-691B6575-45BA-4672-B760-588237661575Q26751021-B0E1C40A-08B4-47DB-B281-926EAB78A510Q26751387-20ABC327-E4E2-45FF-81B3-9EF3AE2D8ED6Q26752834-69366584-5C4C-40B1-8EDA-35D7FB4EC47BQ26753160-622F617F-3D30-4B00-88B2-8B2A9E7640E4Q26764987-FF4D35E5-37C0-4398-8604-6E2E22766509Q26770482-CE6CBE4D-6101-42BE-B7BB-26C3057D432BQ26771541-E1B3BFB3-C081-413C-92C0-72D2F913FAEBQ26773012-3D30ED63-9EE1-4EB2-B904-6911EF480E0AQ26775361-ABBF2332-480E-4F37-B283-5D320326CAF5Q26777683-1A9233BD-1B25-4C4C-9C0A-8CF415BE4C9EQ26777734-DCC2E225-8C71-4F8D-BCA4-67C67C2FB420Q26781187-9B94AADA-733C-4E8D-9A4F-3D74B2A1C65BQ26783705-D79454C9-5AAC-420D-BE9A-9EC3A2E09DC4Q26785496-FF8D8F49-3FF6-4E01-A44A-969C18E7C274Q26795751-20E9BE54-D574-47D3-9172-0857B19790FCQ26866393-F221EE96-BD92-4DC4-B173-08DC971BF438Q27343148-735F91E0-8A6C-4276-BDC9-ACB70D36F51FQ27612411-554BB5E4-7E83-4057-B4E0-5632C9B412FEQ27853170-DE9EF243-E0E6-447A-8830-A62AB8B6EB95Q28069626-490C4F1E-EF08-4C34-81DD-4AA4B99DEE96Q28069856-0DC7483E-CC58-42DF-ADD5-77E2B3CB5576Q28069910-A4D75F46-7529-45A1-B82B-BBB5667EF726Q28072074-EE731F17-FFB1-454A-8657-3D4EA550FD15Q28072755-939AC8B6-65EB-4EC4-88AB-4D84414D07BEQ28072793-097ACB34-E8ED-4CB3-83D7-46172CE5DCFEQ28074156-EF48703B-7F54-4CFB-AF59-353254B96B08Q28076296-14ACF95A-02AF-4B1D-AE5A-18F1AF8C981AQ28076777-1F094BAF-0D50-41FE-AFF3-B44574AB13A8Q28077183-570A7A58-CC4C-4511-A55B-3E47F5058646Q28078951-A27424AF-1BE2-4EAC-AFE3-F40931F2B8B0Q28080469-D2764228-1174-4827-8E08-60C65E355B80Q28081872-94AA0A29-3CB2-43BE-A2F0-0AB73BE67CED
P2860
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
The cyclin-dependent kinase 4/ ...... ): a randomised phase 2 study.
@ast
The cyclin-dependent kinase 4/ ...... ): a randomised phase 2 study.
@en
The cyclin-dependent kinase 4/ ...... ): a randomised phase 2 study.
@nl
type
label
The cyclin-dependent kinase 4/ ...... ): a randomised phase 2 study.
@ast
The cyclin-dependent kinase 4/ ...... ): a randomised phase 2 study.
@en
The cyclin-dependent kinase 4/ ...... ): a randomised phase 2 study.
@nl
prefLabel
The cyclin-dependent kinase 4/ ...... ): a randomised phase 2 study.
@ast
The cyclin-dependent kinase 4/ ...... ): a randomised phase 2 study.
@en
The cyclin-dependent kinase 4/ ...... ): a randomised phase 2 study.
@nl
P2093
P3181
P1433
P1476
The cyclin-dependent kinase 4/ ...... ): a randomised phase 2 study.
@en
P2093
Anu R Thummala
Camilla Fowst
Dennis J Slamon
Istvan Lang
Johannes Ettl
John P Crown
Katalin Boer
Marcus Schmidt
Nataliya L Voytko
Ravindranath Patel
P3181
P356
10.1016/S1470-2045(14)71159-3
P577
2015-01-01T00:00:00Z